#USA #Carlsbad #Pictor Holdings #Mycoplasma bovis #PictVet

Pictor's Proteomics Platform: A New Era in Mycoplasma bovis Detection

In an exciting development for cattle health, Pictor Holdings Inc. has unveiled its state-of-the-art PictVet™ Mycoplasma bovis IgG MultiplexELISA. This advanced assay promises significant gains in accurately detecting the severe pathogen Mycoplasma bovis, which has been wreaking havoc on cattle populations worldwide. Economic implications in the United States alone are staggering, with losses exceeding $100 million each year due to mastitis resulting from this infection. Although Mycoplasma bovis isn't a risk to human health, it poses challenges for public health systems concerning antimicrobial resistance, food security, and resource allocation.

The PictVet™ assay's enhanced analytical performance and potential impacts were highlighted in a recently published study, which received support from New Zealand's Ministry for Primary Industries and the University of Melbourne. The new assay reported remarkable results, with a Positive Percent Agreement (PPA) of 100%, a Negative Percent Agreement (NPA) of 98.4%, and an overall agreement of 98.9% when compared to the existing IDvet ELISA method. This effectiveness is attributed to a unique multiplex design employing two specific Mycoplasma bovis antigens, thereby boosting both sensitivity and specificity.

Dr. Yoichi Furuya, Pictor's Chief Science Officer, expressed the significance of the PictVet™ assay: “By incorporating multiple antigens, this assay establishes a new benchmark for veterinary testing. Its innovation allows for earlier and more reliable detection of Mycoplasma bovis infections, which is essential for effective management of this disease.”

Furthermore, the assay's limit of detection (LOD) greatly surpasses current methodologies, giving it the capability to identify infections even at lower antibody concentrations. Plans for further studies are in motion to assess its effectiveness across diverse field conditions for early detection of Mycoplasma bovis.

Dr. Paul Dick, President of Paul Dick Associates Ltd., stated, “Mycoplasma bovis continues to inflict a heavy toll on the global cattle industry—contributing to production losses, worsening animal welfare, and affecting food security and antimicrobial resistance. Accurate, reliable, and cost-effective testing is indispensable. Without it, we are navigating blind, delaying critical decisions that farmers and veterinarians need to ensure herd health and maintain food systems.”

The PictVet™ assay addresses shortcomings in existing surveillance tools, providing a more dependable strategy for managing Mycoplasma bovis outbreaks. This early and precise detection capability is vital for supporting eradication initiatives, such as New Zealand's extensive campaign, while ensuring the health and welfare of cattle worldwide.

Dr. Jamie Platt, CEO of Pictor, remarked on the transformative nature of the assay: “It is more than just a laboratory instrument; it is a solution that empowers veterinarians and farmers to actively manage herd health.” Pictor is committed to pushing boundaries in innovating solutions that yield significant impacts in both human and animal health under the One Health initiative.

Pictor stands out as a leader in flexible, targeted proteomics, providing next-generation multiplex solutions designed to empower health providers—clinically, diagnostically, and in veterinary capacities. Utilizing the patented PictArray™, PictImager™, and AI-based Pictorial™ software, Pictor's platform enables thorough insights from singular samples, resulting in quicker, more economical, and scalable outputs.

From advancements in infectious diseases to oncology, Pictor is dedicated to enhancing testing capabilities that foster improved health outcomes for humans and animals alike. Headquartered in Carlsbad, California, the company is unwavering in its mission to deliver innovations marked by outstanding performance and cost efficiency.

To discover more about how Pictor is pioneering the future of proteomics testing, visit their website www.pictordx.com.